Ionis Pharmaceuticals Inc IONS
We take great care to ensure that the data presented and summarized in this overview for IONIS PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IONS
View all-
Vanguard Group Inc Valley Forge, PA16.7MShares$688 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16MShares$661 Million0.4% of portfolio
-
Capital World Investors Los Angeles, CA12.5MShares$516 Million0.08% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$425 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.85MShares$323 Million7.06% of portfolio
-
Wellington Management Group LLP Boston, MA6.35MShares$261 Million0.05% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.89MShares$201 Million6.86% of portfolio
-
State Street Corp Boston, MA4.53MShares$187 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.8MShares$156 Million0.27% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$129 Million0.01% of portfolio
Latest Institutional Activity in IONS
Top Purchases
Top Sells
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Transactions at IONS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2025
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.75%
|
$210,000
$42.25 P/Share
|
|
Aug 05
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-10.05%
|
$420,000
$42.86 P/Share
|
|
Aug 04
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
9,549
-15.64%
|
$401,058
$42.8 P/Share
|
|
Jul 30
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,432
-1.33%
|
$109,440
$45.0 P/Share
|
|
Jul 30
2025
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,432
+1.32%
|
$77,824
$32.6 P/Share
|
|
Jul 15
2025
|
Joseph Loscalzo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+10.09%
|
-
|
|
Jul 15
2025
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+2.55%
|
-
|
|
Jul 15
2025
|
Allene M. Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+17.09%
|
-
|
|
Jul 15
2025
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+6.99%
|
-
|
|
Jul 15
2025
|
Joan E Herman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+8.13%
|
-
|
|
Jul 15
2025
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+4.27%
|
-
|
|
Jul 15
2025
|
Joseph H Wender Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,079
+2.89%
|
-
|
|
Jul 15
2025
|
Michael J. Yang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+40.43%
|
-
|
|
Jul 11
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,160
-0.64%
|
$47,560
$41.74 P/Share
|
|
May 01
2025
|
Michael R Hayden Director |
BUY
Open market or private purchase
|
Direct |
15,000
+23.0%
|
$465,000
$31.86 P/Share
|
|
Apr 16
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,928
-10.96%
|
$109,984
$28.4 P/Share
|
|
Apr 16
2025
|
Kyle Jenne EVP, Chf GL Pdt Str Ofcr |
SELL
Open market or private sale
|
Direct |
3,016
-21.22%
|
$84,448
$28.36 P/Share
|
|
Apr 16
2025
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
680
-1.19%
|
$19,040
$28.37 P/Share
|
|
Apr 15
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,837
+23.21%
|
-
|
|
Apr 15
2025
|
Kyle Jenne EVP, Chf GL Pdt Str Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
12,226
+46.24%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 290K shares |
|---|---|
| Open market or private purchase | 20K shares |
| Grant, award, or other acquisition | 48.5K shares |
| Other acquisition or disposition | 3.15K shares |
| Open market or private sale | 217K shares |
|---|